Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice

被引:154
作者
Dineen, Sean P. [1 ,2 ]
Lynn, Kristi D. [1 ,2 ]
Holloway, Shane E. [1 ,2 ]
Miller, Andrew F. [1 ,2 ]
Sullivan, James P. [1 ]
Shames, David S. [1 ]
Beck, Adam W. [1 ,2 ]
Barnett, Carlton C. [1 ,2 ]
Fleming, Jason B. [4 ]
Brekken, Rolf A. [1 ,2 ,3 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
D O I
10.1158/0008-5472.CAN-07-6705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Macrophages are an abundant inflammatory cell type in the tumor microenvironment that can contribute to tumor growth and metastasis. Macrophage recruitment into tumors is mediated by multiple cytokines, including vascular endothelial growth factor (VEGF), which is thought to function primarily through VEGF receptor (VEGFR) 1 expressed on macrophages. Macrophage infiltration is affected by VEGF inhibition. We show that selective inhibition of VEGFR2 reduced macrophage infiltration into orthotopic pancreatic tumors. Our studies show that tumor-associated macrophages express VEGFR2. Furthermore, peritoneal macrophages from tumor-bearing animals express VEGFR2, whereas peritoneal macrophages from non-tumor-bearing animals do not. To our knowledge, this is the first time that tumor-associated macrophages have been shown to express VEGFR2. Additionally, we found that the cytokine pleiotrophin is sufficient to induce VEGFR2 expression on macrophages. Pleiotrophin has previously been shown to induce expression of endothelial cell markers on macrophages and was present in the microenvironment of orthotopic pancreatic tumors. Finally, we show that VEGFR2, when expressed by macrophages, is essential for VEGF-stimulated migration of tumor-associated macrophages. In summary, tumor-associated macrophages express VEGFR2, and selective inhibition of VEGFR2 reduces recruitment of macrophages into orthotopic pancreatic tumors. Our results show an underappreciated mechanism of action that may directly contribute to the antitumor activity of angiogenesis inhibitors that block the VEGFR2 pathway.
引用
收藏
页码:4340 / 4346
页数:7
相关论文
共 37 条
[1]   Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice [J].
Beck, AW ;
Luster, TA ;
Miller, AF ;
Holloway, SE ;
Conner, CR ;
Barnett, CC ;
Thorpe, PE ;
Fleming, JB ;
Brekken, RA .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (10) :2639-2643
[2]  
Brekken RA, 1998, CANCER RES, V58, P1952
[3]  
Brekken RA, 2000, CANCER RES, V60, P5117
[4]   Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment [J].
Chang, Yunchao ;
Zuka, Masahiko ;
Perez-Pinera, Pablo ;
Astudillo, Aurora ;
Mortimer, Joanne ;
Berenson, James R. ;
Deuel, Thomas F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) :10888-10893
[5]  
Choudhuri R, 1997, CANCER RES, V57, P1814
[6]   Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis [J].
Condeelis, J ;
Pollard, JW .
CELL, 2006, 124 (02) :263-266
[7]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[8]   Paradoxical roles of the immune system during cancer development [J].
de Visser, KE ;
Eichten, A ;
Coussens, LM .
NATURE REVIEWS CANCER, 2006, 6 (01) :24-37
[9]   Pleiotrophin: A cytokine with diverse functions and a novel signaling pathway [J].
Deuel, TF ;
Zhang, N ;
Yeh, HJ ;
Silos-Santiago, I ;
Wang, ZY .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 397 (02) :162-171
[10]   Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers [J].
Duda, Dan G. ;
Jain, Rakesh K. ;
Willett, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) :4033-4042